PPOS (Progestin Primed Ovarian Stimulation) and Corifollitropin Alfa (CFA) Cross-over Study

Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexFemale
Age18-40
SponsorUniversity Hospital, Ghent

About this trial

P-CCROSS is a randomized, prospective monocentric phase 4 study with a crossover study design. The aim of the study is to compare patient satisfaction (by means of questionnaires) and treatment compliance with IVF treatment with CFA (corifollitropin alfa) and PPOS (Progestin-Primed Ovarian Stimulation) versus conventional IVF treatment with a recombinant FSH/GnRH antagonist. The study will also compare patients undergoing elective fertility preservation versus PGT-A (pre-implantation genetic testing for aneuploidy) patients.The study will have a crossover design so that patients will receive both forms of treatment. The investigators will also compare the endocrine profile and ovarian response of CFA/PPOS versus rFSH/GnRH ovarian stimulation cycles.

Eligibility criteria

Qualifiers

Group 1: indication for oocyte cryopreservation

Group 2: indication for IVF/ICSI and PGT-A

First ovarian stimulation cycle

Aged ≥ 18 and < 41 years old at the time of first OPU

Disqualifiers

contra-indication for ovarian stimulation

expected poor ovarian response (Bologna Criteria)

PCOS patients

refusal to fill out questionnaires before, during and after treatment

Trial design

Treatments tested in this trial

  • Elonva®
  • Puregon®
  • Orgalutran®
  • Gonapeptyl®
  • Cerazette®

Treatment groups

60 Participants
are divided into 2 treatment groups

Sponsors and collaborators